Introduction

Sequelae of chronic infection with hepatitis B virus (HBV) include chronic hepatitis, compensated cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC) (1, 2). Several studies have demonstrated that long-standing necro-inflammation and viral replication strongly influence the rate of progression to cirrhosis and development of HCC (3-5). Conceivably, these patients are accompanied by a risk of hepatic decompensation and the development of HCC, and antiviral therapy such as suppression of HBV replication and necro-inflammation by interferon or nucleotide analogs may reduce the risk of these complications and prolong survival.
HCC is characterized by a high incidence of intrahepatic recurrence, including intrahepatic metastasis and multicentric occurrence, even after curative treatment (6) (7) (8) (9) ; therefore, most patients with recurrent HCC need to be treated repeatedly. Although hepatic resection and radiofrequency ablation (RFA) are recognized as curative treatments, many cirrhotic patients cannot repeatedly undergo curative treatments due to the deterioration of liver function after treatment. Furthermore, liver function is the most critical prognostic factor of treatment for HCC (10) (11) (12) . It is very important to maintain adequate liver function when undergoing therapy and to suppress the recurrence of HCC in order to improve survival; however, HBV-related chronic liver disease gradually progresses to cirrhosis and hepatic decompensation, and leads to a higher probability of contracting HCC. Recently, nucleotide analogs such as lamivudine, adefovir dipivoxil and entecavir have been reported to inhibit the replication of HBV and reduce hepatic necro-inflammation (13) (14) (15) (16) . Thus, the suppression of HBV in HBV-related chronic hepatitis and cirrhosis prevents the progress of liver failure and the development of HCC (17, 18) .
However, few papers have reported the benefit of nucleotide analogs in the outcome after treatment for HCC (19) (20) (21) 
Statistical Analysis
Data analyses were performed using Stat View version 5.0 (SAS Institute Inc; Cary, NC, USA). Continuous variables are expressed as the mean ± SD (standard deviation). For quantitative variables, chi-squared test or Fisher's exact probability test was performed as appropriate. For continuous variables, Student's t-test or the
Results
Baseline characteristics
The baseline characteristics of the nucleotide analog and control groups are summarized in Table 1 
T a b l e 1 . B a s e l i n e Ch a r a c t e r i s t i c s o f Nu c l e o t i d e An a l o g a n d Co n t r o l Gr o u p s
Changes in liver function tests
Each parameter of albumin, AST and ALT significantly improved after nucleotide analog administration compared with the baseline, but total bilirubin, platelet count and prothrombin time did not change (Figs. 1-A, C, 2-A, C) . The Child-Pugh scores in the nucleotide analog group were significantly decreased compared with the baseline value although those in the control group were significantly increased (Fig. 3) .
We (Fig. 1-B) . There was a significant difference between the groups. Similarly, AST, ALT and prothrombin time in the nucleotide analog group were significantly improved compared with the control group (Fig. 1-D, 2-B, D) .
We (Fig. 4) (Fig. 5-A) ; however, there was a significant difference in the cumulative survival rate between the groups in patients who underwent curative treatment (p=0.047) (Fig. 5-B (19) and Kuzuya et al (20) (17) and a multicenter retrospective study (18) . Furthermore, elevated HBV DNA levels were reported to be strong risk predictors of HCC recurrence (21) (14, 15, 17, 18 
F i g u r e 1 . S e r i a l c h a n g e s i n ( A) s e r u m a l b u mi n a n d ( C) t o t a l b i l i r u b i n i n t h e n u c l e o t i d e a n a l o g g r o u p ( ○) a n d t h e c o n t r o l g r o u p ( •) . * : p < 0 . 0 5 v s b a s e l i n e Ch a n g e s f r o m b a s e l i n e t o t h e r e -t r e a t me n t t i me b e t we e n t h e n u c l e o t i d e a n a l o g g r o u p ( ○) a n d t h e c o n t r o l g r o u p ( •) i n c u r a t i v e l y t r e a t e d HCC p a t i e n t s we r e c o mp a r e d u s i n g r e p e a t e d -me a s u r e s a n a l y s i s o f v a r i a n c e ( B : a l b u mi n , D: t o t a l b i l i r u b i n ) .
F i g u r e 2 . S e r i a l c h a n g e s i n ( A) a l a n i n e a mi n o t r a n s f e r a s e ( AL T ) a n d ( C) p r o t h r o mb i n t i me i n t h e n u c l e o t i d e a n a l o g g r o u p ( ○) a n d t h e c o n t r o l g r o u p ( •) . * : p < 0 . 0 5 v s b a s e l i n e Ch a n g e s f r o m b a s e l i n e t o t h e r e -t r e a t me n t t i me b e t we e n t h e n u c l e o t i d e a n a l o g g r o u p ( ○) a n d t h e c o n t r o l g r o u p ( •) i n c u r a t i v e l y t r e a t e d HCC p a t i e n t s we r e c o mp a r e d u s i n g r e p e a t e d -me a s u r e s a n a l y s i s o f v a r i a n c e ( B : AL T , D: p r o t h r o mb i n t i me ) .
F i g u r e 3 . S e r i a l c h a n g e s i n t h e Ch i l d -P u g h s c o r e i n t h e n u c l e o t i d e a n a l o g g r o u p ( ○) a n d t h e c o nt r o l g r o u p ( •) . T h e Ch i l d -P u g h s c o r e i n t h e n u c l e o t i d e a n a l o g g r o u p wa s s i g n i f i c a n t l y d e c r e a s e d c o mp a r e d wi t h t h e b a s e l i n e v
